Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
JHEP Reports : Innovation in Hepatology|August 18, 2023
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022Pietro Lampertico, Elisabetta Degasperi, Lisa Sandmann, et al.
Current Opinion in Virology|April 19, 2017
Direct-acting antivirals: the endgame for hepatitis C?Roberta D'Ambrosio, Elisabetta Degasperi, Massimo Colombo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 20, 2025
Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024Elisabetta Degasperi, Lisa Sandmann, Heiner Wedemeyer, et al.
Expert Review of Anti-Infective Therapy|May 1, 2013
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year historyElisabetta Degasperi, Mauro Viganò, Alessio Aghemo, et al.
Expert Opinion on Biological Therapy|December 23, 2011
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical managementMauro Viganò, Elisabetta Degasperi, Alessio Aghemo, et al.
Expert Review of Gastroenterology & Hepatology|October 11, 2016
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infectionElisabetta Degasperi, Flavio Caprioli, Omar El Sherif, et al.
Journal of Viral Hepatitis|June 10, 2019
TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antiviralsElisabetta Degasperi, Enrico Galmozzi, Floriana Facchetti, et al.
The American Journal of Gastroenterology|February 19, 2021
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker TherapyGiulia Tosetti, Elisabetta Degasperi, Elisa Farina, et al.
Plos One|April 25, 2014
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving TelaprevirAlessio Aghemo, Eleonora Grassi, Maria Grazia Rumi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 8, 2019
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV InfectionElisabetta Degasperi, Roberta D'Ambrosio, Massimo Iavarone, et al.
Pageof 9